Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals
The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...
Novavax: Balancing Potential and Risk Amid Strategic Shifts and Uncertain Market Outlook
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
MarketWatch19h
Novavax Inc. stock underperforms Tuesday when compared to competitors
Shares of Novavax Inc. NVAX slid 6.10% to $8.46 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.09% to 19,281.40 ...
MarketWatch21h
Novavax Inc.
Inovio Pharmaceuticals Inc.-3.56% $138.65M ...
Barchart on MSN6h
S&P Futures Tick Lower as Key U.S. Inflation Data Looms
December S&P 500 E-Mini futures (ESZ24) are trending down -0.19% this morning as investors held back from making big bets ...
Novavax price target lowered to $12 from $14 at BofA
BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...
Novavax sees weak Covid vaccine sales, convinced Sanofi can do better
Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...
Wall Street muted as focus moves to economic data
Wall Street's main indexes were little changed on Tuesday following post-election gains over the past few days.
Yahoo Finance20h
Alcon (ALC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a ...